Evaluate the Efficacy and Safety of NTQ5082 Capsules in Patients With Primary IgA Nephropathy

Exclusion Criteria

• •1. Receipt of aldosterone receptor antagonists, renin inhibitors, or medications significantly affecting creatinine levels within 4 weeks or 5 half-lives (whichever is longer) before first investigational product administration.
• •2. Continuous use of systemic corticosteroids, immunosuppressants/modulators, or Chinese herbal medicines with immunosuppressive effects within 12 weeks or 5 half-lives (whichever is longer) before first investigational product administration.
• •3. Treatment with biological agents or complement pathway inhibitors (other than the study drug) within 12 weeks or 5 half-lives (whichever is longer) before first investigational product administration.
• •4. History of gastrointestinal surgery potentially altering drug absorption/distribution/metabolism/excretion, severe gastrointestinal disorders, or conditions causing dysphagia/recurrent vomiting that may interfere with oral medication intake.
• •5. Major trauma/surgery within 12 weeks before screening or planned major surgery during the study.
• •6. Previous bone marrow/hematopoietic stem cell transplantation or solid organ transplantation (e.g., heart, lung, kidney, liver).
• •7. Known/suspected hereditary complement deficiency, or diagnosed primary/severe secondary immunodeficiency.
• •8. Poorly controlled blood pressure as assessed by the investigator.
• •9. Poorly controlled blood glucose as assessed by the investigator.
• •10. Presence of nephrotic syndrome, rapidly progressive glomerulonephritis, renal pathology showing \>50% glomerular crescents, or \>50% tubular atrophy-interstitial fibrosis.
• •11. Participation in other interventional clinical trials with pharmacological/device interventions within 4 weeks before screening.
• •12. Pregnant/lactating women or those planning pregnancy during the study